TRLV
Price
$8.65
Change
+$0.08 (+0.93%)
Updated
Jul 31 closing price
Capitalization
1.66B
4 days until earnings call
Intraday BUY SELL Signals
YCBD
Price
$0.51
Change
+$0.04 (+8.51%)
Updated
Jul 31 closing price
Capitalization
5.32M
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

TRLV vs YCBD

TRLV vs YCBD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
TRLV vs. YCBD commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TRLV is a Hold and YCBD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (TRLV: $8.65 vs. YCBD: $0.51)
Brand notoriety: TRLV and YCBD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TRLV: 54% vs. YCBD: 80%
Market capitalization -- TRLV: $1.66B vs. YCBD: $5.32M
TRLV [@Pharmaceuticals: Generic] is valued at $1.66B. YCBD’s [@Pharmaceuticals: Generic] market capitalization is $5.32M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TRLV’s FA Score shows that 1 FA rating(s) are green whileYCBD’s FA Score has 2 green FA rating(s).

  • TRLV’s FA Score: 1 green, 4 red.
  • YCBD’s FA Score: 2 green, 3 red.
According to our system of comparison, both TRLV and YCBD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TRLV’s TA Score shows that 2 TA indicator(s) are bullish while YCBD’s TA Score has 3 bullish TA indicator(s).

  • TRLV’s TA Score: 2 bullish, 5 bearish.
  • YCBD’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both TRLV and YCBD are a bad buy in the short-term.

Price Growth

TRLV (@Pharmaceuticals: Generic) experienced а +3.47% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -5.78% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.61%. For the same industry, the average monthly price growth was -5.02%, and the average quarterly price growth was +19.02%.

Reported Earning Dates

TRLV is expected to report earnings on Aug 07, 2026.

YCBD is expected to report earnings on Aug 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRLV($1.66B) has a higher market cap than YCBD($5.32M). TRLV YTD gains are higher at: -0.460 vs. YCBD (-62.452).
TRLVYCBDTRLV / YCBD
Capitalization1.66B5.32M31,254%
EBITDAN/A-957.09K-
Gain YTD-0.460-62.4521%
P/E RatioN/A0.21-
RevenueN/A20M-
Total CashN/A2.64M-
Total DebtN/A415K-
FUNDAMENTALS RATINGS
TRLV vs YCBD: Fundamental Ratings
TRLV
YCBD
OUTLOOK RATING
1..100
6852
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
4488
P/E GROWTH RATING
1..100
192
SEASONALITY SCORE
1..100
1650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YCBD's Valuation (28) in the Other Consumer Services industry is somewhat better than the same rating for TRLV (71) in the null industry. This means that YCBD’s stock grew somewhat faster than TRLV’s over the last 12 months.

YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as TRLV (100) in the null industry. This means that YCBD’s stock grew similarly to TRLV’s over the last 12 months.

TRLV's SMR Rating (94) in the null industry is in the same range as YCBD (99) in the Other Consumer Services industry. This means that TRLV’s stock grew similarly to YCBD’s over the last 12 months.

TRLV's Price Growth Rating (44) in the null industry is somewhat better than the same rating for YCBD (88) in the Other Consumer Services industry. This means that TRLV’s stock grew somewhat faster than YCBD’s over the last 12 months.

YCBD's P/E Growth Rating (2) in the Other Consumer Services industry is in the same range as TRLV (19) in the null industry. This means that YCBD’s stock grew similarly to TRLV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TRLVYCBD
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
TRLV
Daily Signal:
Gain/Loss:
YCBD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GLMD0.620.02
+3.67%
Galmed Pharmaceuticals Ltd
EXPD167.890.88
+0.53%
Expeditors International of Washington
VATE8.12N/A
N/A
INNOVATE Corp
VAC97.51-0.08
-0.08%
MARRIOTT VACATIONS WORLDWIDE Corp
NMFC6.89-0.02
-0.29%
New Mountain Finance Corp

TRLV and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRLV has been closely correlated with GLAS. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRLV jumps, then GLAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRLV
1D Price
Change %
TRLV100%
+0.93%
GLAS - TRLV
75%
Closely correlated
-3.74%
CGC - TRLV
69%
Closely correlated
-0.08%
ACB - TRLV
65%
Loosely correlated
-1.41%
CRON - TRLV
61%
Loosely correlated
-2.08%
OGI - TRLV
54%
Loosely correlated
-2.96%
More